Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1999 Apr;52(4):278–282. doi: 10.1136/jcp.52.4.278

Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients.

I Cohen 1, E Perel 1, D Flex 1, R Tepper 1, M M Altaras 1, M Cordoba 1, Y Beyth 1
PMCID: PMC501333  PMID: 10474520

Abstract

AIMS: To evaluate whether endometrial pathology is more likely to be diagnosed in gynaecologically symptomatic rather than in gynaecologically asymptomatic postmenopausal breast cancer patients with tamoxifen treatment; and to evaluate the possible influence of various clinical factors on the incidence of endometrial pathology. METHODS: Endometrial histological findings, transvaginal ultrasonographic endometrial thickness, demographic characteristics, health habits, and risk factors for endometrial cancer were compared between 14 gynaecologically symptomatic (group I) and 224 gynaecologically asymptomatic (group II) postmenopausal breast cancer patients with tamoxifen treatment. RESULTS: Overall, 28.6% of the study population had endometrial pathology. The incidence of overall positive endometrial histological findings was significantly higher in group I than in group II (92.9% v 24.6%, p < 0.0001). Atrophic endometrium was more common in group II than in group I (75.3% v 7.1%, p < 0.0001). Most other endometrial pathology was significantly more common in group I than in group II (endometrial hyperplasia, 35.7% v 5.6%, p < 0.0001; endometrial polyps, 35.7% v 13.4%, p < 0.0111; endometrial carcinoma, 21.5% v 0.9%, p < 0.0001). Endometrial pathology appeared considerably later in the gynaecologically asymptomatic patients than in gynaecologically symptomatic patients (p = 0.0002). Vaginal bleeding or spotting occurred exclusively in group I. The incidence of endometrial pathology in the entire study population was consistent with that reported elsewhere, and higher than that reported for healthy postmenopausal women. CONCLUSIONS: Endometrial pathology is more likely to be diagnosed in gynaecologically symptomatic postmenopausal breast cancer patients with tamoxifen treatment, and after a shorter duration of time, than in gynaecologically asymptomatic patients.

Full text

PDF
278

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson M., Storm H. H., Mouridsen H. T. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst. 1991 Jul 17;83(14):1013–1017. doi: 10.1093/jnci/83.14.1013. [DOI] [PubMed] [Google Scholar]
  2. Barakat R. R., Wong G., Curtin J. P., Vlamis V., Hoskins W. J. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol. 1994 Nov;55(2):164–168. doi: 10.1006/gyno.1994.1271. [DOI] [PubMed] [Google Scholar]
  3. Bornstein J., Auslender R., Pascal B., Gutterman E., Isakov D., Abramovici H. Diagnostic pitfalls of ultrasonographic uterine screening in women treated with tamoxifen. J Reprod Med. 1994 Sep;39(9):674–678. [PubMed] [Google Scholar]
  4. Cheng W. F., Lin H. H., Torng P. L., Huang S. C. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol. 1997 Aug;66(2):233–237. doi: 10.1006/gyno.1997.4739. [DOI] [PubMed] [Google Scholar]
  5. Cohen I., Altaras M. M., Shapira J., Tepper R., Cordoba M., Figer A., Zalel Y., Dror Y., Beyth Y. Different coexisting endometrial histological features in asymptomatic postmenopausal breast cancer patients treated with tamoxifen. Gynecol Obstet Invest. 1997;43(1):60–63. doi: 10.1159/000291821. [DOI] [PubMed] [Google Scholar]
  6. Cohen I., Altaras M. M., Shapira J., Tepper R., Rosen D. J., Cordoba M., Zalel Y., Figer A., Yigael D., Beyth Y. Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients. Int J Gynecol Pathol. 1996 Apr;15(2):152–157. doi: 10.1097/00004347-199604000-00010. [DOI] [PubMed] [Google Scholar]
  7. Cohen I., Rosen D. J., Shapira J., Cordoba M., Gilboa S., Altaras M. M., Yigael D., Beyth Y. Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol. 1993 Jun;100(6):567–570. doi: 10.1111/j.1471-0528.1993.tb15310.x. [DOI] [PubMed] [Google Scholar]
  8. Cohen I., Rosen D. J., Shapira J., Cordoba M., Gilboa S., Altaras M. M., Yigael D., Beyth Y. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol. 1994 Feb;52(2):185–190. doi: 10.1006/gyno.1994.1029. [DOI] [PubMed] [Google Scholar]
  9. Cohen I., Tepper R., Rosen D. J., Shapira J., Cordoba M., Dror Y., Altaras M., Beyth Y. Continuous tamoxifen treatment in asymptomatic, postmenopausal breast cancer patients does not cause aggravation of endometrial pathologies. Gynecol Oncol. 1994 Oct;55(1):138–143. doi: 10.1006/gyno.1994.1263. [DOI] [PubMed] [Google Scholar]
  10. Cook L. S., Weiss N. S., Schwartz S. M., White E., McKnight B., Moore D. E., Daling J. R. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst. 1995 Sep 20;87(18):1359–1364. doi: 10.1093/jnci/87.18.1359. [DOI] [PubMed] [Google Scholar]
  11. Corley D., Rowe J., Curtis M. T., Hogan W. M., Noumoff J. S., Livolsi V. A. Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol. 1992 Jan;79(1):111–116. [PubMed] [Google Scholar]
  12. Creasman W. T. Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment. Semin Oncol. 1997 Feb;24(1 Suppl 1):S1–140-S1-50. [PubMed] [Google Scholar]
  13. Cuenca R. E., Giachino J., Arredondo M. A., Hempling R., Edge S. B. Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use. Cancer. 1996 May 15;77(10):2058–2063. doi: 10.1002/(SICI)1097-0142(19960515)77:10<2058::AID-CNCR14>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  14. Curtis R. E., Boice J. D., Jr, Shriner D. A., Hankey B. F., Fraumeni J. F., Jr Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst. 1996 Jun 19;88(12):832–834. doi: 10.1093/jnci/88.12.832. [DOI] [PubMed] [Google Scholar]
  15. De Muylder X., Neven P., De Somer M., Van Belle Y., Vanderick G., De Muylder E. Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynaecol Obstet. 1991 Oct;36(2):127–130. doi: 10.1016/0020-7292(91)90767-y. [DOI] [PubMed] [Google Scholar]
  16. Fisher B., Costantino J. P., Redmond C. K., Fisher E. R., Wickerham D. L., Cronin W. M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994 Apr 6;86(7):527–537. doi: 10.1093/jnci/86.7.527. [DOI] [PubMed] [Google Scholar]
  17. Fornander T., Hellström A. C., Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst. 1993 Nov 17;85(22):1850–1855. doi: 10.1093/jnci/85.22.1850. [DOI] [PubMed] [Google Scholar]
  18. Gal D., Kopel S., Bashevkin M., Lebowicz J., Lev R., Tancer M. L. Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer--preliminary report. Gynecol Oncol. 1991 Aug;42(2):120–123. doi: 10.1016/0090-8258(91)90330-8. [DOI] [PubMed] [Google Scholar]
  19. Hann L. E., Giess C. S., Bach A. M., Tao Y., Baum H. J., Barakat R. R. Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings. AJR Am J Roentgenol. 1997 Mar;168(3):657–661. doi: 10.2214/ajr.168.3.9057510. [DOI] [PubMed] [Google Scholar]
  20. Ismail S. M. Pathology of endometrium treated with tamoxifen. J Clin Pathol. 1994 Sep;47(9):827–833. doi: 10.1136/jcp.47.9.827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kedar R. P., Bourne T. H., Powles T. J., Collins W. P., Ashley S. E., Cosgrove D. O., Campbell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet. 1994 May 28;343(8909):1318–1321. doi: 10.1016/s0140-6736(94)92466-x. [DOI] [PubMed] [Google Scholar]
  22. Killackey M. A., Hakes T. B., Pierce V. K. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep. 1985 Feb;69(2):237–238. [PubMed] [Google Scholar]
  23. Lahti E., Blanco G., Kauppila A., Apaja-Sarkkinen M., Taskinen P. J., Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol. 1993 May;81(5 ):660–664. [PubMed] [Google Scholar]
  24. Magriples U., Naftolin F., Schwartz P. E., Carcangiu M. L. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol. 1993 Mar;11(3):485–490. doi: 10.1200/JCO.1993.11.3.485. [DOI] [PubMed] [Google Scholar]
  25. Malfetano J. H. Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol. 1990 Oct;39(1):82–84. doi: 10.1016/0090-8258(90)90404-9. [DOI] [PubMed] [Google Scholar]
  26. Multicentre randomised clinical trial of chorion villus sampling and amniocentesis. First report. Canadian Collaborative CVS-Amniocentesis Clinical Trial Group. Lancet. 1989 Jan 7;1(8628):1–6. [PubMed] [Google Scholar]
  27. Neven P., De Muylder X., Van Belle Y., Vanderick G., De Muylder E. Tamoxifen and the uterus and endometrium. Lancet. 1989 Feb 18;1(8634):375–375. [PubMed] [Google Scholar]
  28. Nuovo M. A., Nuovo G. J., McCaffrey R. M., Levine R. U., Barron B., Winkler B. Endometrial polyps in postmenopausal patients receiving tamoxifen. Int J Gynecol Pathol. 1989;8(2):125–131. doi: 10.1097/00004347-198906000-00005. [DOI] [PubMed] [Google Scholar]
  29. Ribeiro G., Swindell R. The Christie hospital adjuvant tamoxifen trial--status at 10 years. Br J Cancer. 1988 Jun;57(6):601–603. doi: 10.1038/bjc.1988.136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Robinson D. C., Bloss J. D., Schiano M. A. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Gynecol Oncol. 1995 Nov;59(2):186–190. doi: 10.1006/gyno.1995.0005. [DOI] [PubMed] [Google Scholar]
  31. Rutqvist L. E., Johansson H., Signomklao T., Johansson U., Fornander T., Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst. 1995 May 3;87(9):645–651. doi: 10.1093/jnci/87.9.645. [DOI] [PubMed] [Google Scholar]
  32. Sasco A. J., Chaplain G., Amoros E., Saez S. Endometrial cancer following breast cancer: Effect of tamoxifen and castration by radiotherapy. Epidemiology. 1996 Jan;7(1):9–13. doi: 10.1097/00001648-199601000-00003. [DOI] [PubMed] [Google Scholar]
  33. Segna R. A., Dottino P. R., Deligdisch L., Cohen C. J. Tamoxifen and endometrial cancer. Mt Sinai J Med. 1992 Oct;59(5):416–418. [PubMed] [Google Scholar]
  34. Seoud M. A., Johnson J., Weed J. C., Jr Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol. 1993 Aug;82(2):165–169. [PubMed] [Google Scholar]
  35. Silva E. G., Tornos C. S., Follen-Mitchell M. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol. 1994 Jul;13(3):248–258. doi: 10.1097/00004347-199407000-00009. [DOI] [PubMed] [Google Scholar]
  36. Tepper R., Beyth Y., Altaras M. M., Zalel Y., Shapira J., Cordoba M., Cohen I. Value of sonohysterography in asymptomatic postmenopausal tamoxifen-treated patients. Gynecol Oncol. 1997 Mar;64(3):386–391. doi: 10.1006/gyno.1996.4568. [DOI] [PubMed] [Google Scholar]
  37. Uziely B., Lewin A., Brufman G., Dorembus D., Mor-Yosef S. The effect of tamoxifen on the endometrium. Breast Cancer Res Treat. 1993;26(1):101–105. doi: 10.1007/BF00682705. [DOI] [PubMed] [Google Scholar]
  38. van Leeuwen F. E., Benraadt J., Coebergh J. W., Kiemeney L. A., Gimbrère C. H., Otter R., Schouten L. J., Damhuis R. A., Bontenbal M., Diepenhorst F. W. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994 Feb 19;343(8895):448–452. doi: 10.1016/s0140-6736(94)92692-1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES